京新药业(002020)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

002020 京新药业

已收盘 04-30 15:00:00

{"stockData":{"symbol":"002020","market":"SZ","secType":"STK","nameCN":"京新药业","latestPrice":13.65,"timestamp":1745996619000,"preClose":13.65,"halted":0,"volume":9590568,"delay":0,"changeRate":0,"floatShares":724000000,"shares":861000000,"eps":0.8177,"marketStatus":"已收盘","change":0,"latestTime":"04-30 15:00:00","open":13.62,"high":13.71,"low":13.44,"amount":130000000,"amplitude":0.0198,"askPrice":13.65,"askSize":23,"bidPrice":13.64,"bidSize":539,"shortable":0,"etf":0,"ttmEps":0.8177,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1746495000000},"marketStatusCode":5,"adr":0,"adjPreClose":13.65,"symbolType":"stock","openAndCloseTimeList":[[1745976600000,1745983800000],[1745989200000,1745996400000]],"highLimit":15.02,"lowLimit":12.29,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":861029140,"isCdr":false,"pbRate":2.07,"roa":"--","peRate":16.693164,"roe":"2.77%","epsLYR":0.83,"committee":-0.140303,"marketValue":11753000000,"turnoverRate":0.0132,"status":2,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2025-05-06。","floatMarketCap":9882000000},"requestUrl":"/m/hq/s/002020","defaultTab":"news","newsList":[{"id":"2531260425","title":"京新药业（002020）2025年一季报简析：净利润减4.62%，应收账款上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2531260425","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531260425?lang=zh_cn&edition=full","pubTime":"2025-04-29 06:10","pubTimestamp":1745878239,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期京新药业发布2025年一季报。截至本报告期末，公司营业总收入9.56亿元，同比下降9.86%，归母净利润1.63亿元，同比下降4.62%。本报告期京新药业应收账款上升，应收账款同比增幅达41.09%。去年的净利率为17.29%，算上全部成本后，公司产品或服务的附加值高。持有京新药业最多的基金为红土创新增强收益债券A，目前规模为12.69亿元，最新净值1.3431，较上一交易日上涨0.07%，近一年上涨3.16%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042900006483.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020"],"gpt_icon":0},{"id":"2530043554","title":"京新药业(002020.SZ)发布一季度业绩，归母净利润1.63亿元，同比下降4.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2530043554","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530043554?lang=zh_cn&edition=full","pubTime":"2025-04-27 17:20","pubTimestamp":1745745600,"startTime":"0","endTime":"0","summary":"京新药业(002020.SZ)发布2025年一季度报告，第一季度，公司实现营业收入9.56亿元，同比下降9.86%。归属于上市公司股东的净利润1.63亿元，同比下降4.62%。归属于上市公司股东的扣除非经常性损益的净利润1.47亿元，同比下降6.45%。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-04-27/doc-ineuqytx7575203.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["002020"],"gpt_icon":0},{"id":"2530804454","title":"京新药业(002020)3月31日股东户数2.57万户，较上期减少8.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2530804454","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530804454?lang=zh_cn&edition=full","pubTime":"2025-04-27 17:08","pubTimestamp":1745744906,"startTime":"0","endTime":"0","summary":"证券之星消息，近日京新药业披露，截至2025年3月31日公司股东户数为2.57万户，较12月31日减少2355.0户，减幅为8.39%。在化学制药行业个股中，京新药业股东户数低于行业平均水平，截至3月31日，化学制药行业平均股东户数为3.15万户。从股价来看，2024年12月31日至2025年3月31日，京新药业区间涨幅为11.09%，在此期间股东户数减少2355.0户，减幅为8.39%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042700006934.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"gpt_icon":0},{"id":"2529395987","title":"京新药业：目前的回购不会影响公司的正常经营","url":"https://stock-news.laohu8.com/highlight/detail?id=2529395987","media":"证券之星","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529395987?lang=zh_cn&edition=full","pubTime":"2025-04-24 20:52","pubTimestamp":1745499167,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)04月23日在投资者关系平台上答复投资者关心的问题。投资者提问：问公司吕董，公司用全体股东的真金白银回购二级市场股票，那为什么不自己掏钱增持公司股份？京新药业回复：您好！目前的回购不会影响公司的正常经营。公司一向重视回报股东，会坚持分红回报股东。谢谢！以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042400038230.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"gpt_icon":0},{"id":"2529074681","title":"京新药业：公司会跟踪相关政策，对于符合快速审核通道规则的品种会积极申请，推动产品尽快上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2529074681","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529074681?lang=zh_cn&edition=full","pubTime":"2025-04-23 21:45","pubTimestamp":1745415911,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业04月23日在投资者关系平台上答复投资者关心的问题。既然脱发剂青少年爱美心切3:2通过走快审通道，京新药业许多仿制药创新药不可以申请快审通道呢？公司会跟踪相关政策，对于符合快速审核通道规则的品种会积极申请，推动产品尽快上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042300040775.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"gpt_icon":0},{"id":"2529681005","title":"京新药业：地达西尼是处方药，公司建议有失眠相关问题的患者在医生诊断后处方使用","url":"https://stock-news.laohu8.com/highlight/detail?id=2529681005","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529681005?lang=zh_cn&edition=full","pubTime":"2025-04-23 21:45","pubTimestamp":1745415910,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业04月23日在投资者关系平台上答复投资者关心的问题。地达西尼推广不力京新药业有关部门必须问责？地达西尼是处方药，公司建议有失眠相关问题的患者在医生诊断后处方使用。京新药业公众号上的用药地图为患者提供当地主要医院的信息，希望为广大患者带来便利性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042300040774.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"gpt_icon":0},{"id":"2529806079","title":"京新药业：公司回购的股份全部存放于公司回购股份专用证券账户中","url":"https://stock-news.laohu8.com/highlight/detail?id=2529806079","media":"证券之星","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529806079?lang=zh_cn&edition=full","pubTime":"2025-04-21 20:51","pubTimestamp":1745239881,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)04月21日在投资者关系平台上答复投资者关心的问题。投资者提问：问公司吕董，公司回购股份是否立马锁定，难道还可以用于转融通吗？京新药业回复：您好！公司回购的股份全部存放于公司回购股份专用证券账户中，不存在转融通情形。谢谢！以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042100029470.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020","161027"],"gpt_icon":0},{"id":"2529880983","title":"京新药业：公司大股东暂未有减持计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2529880983","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529880983?lang=zh_cn&edition=full","pubTime":"2025-04-21 20:51","pubTimestamp":1745239880,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)04月21日在投资者关系平台上答复投资者关心的问题。投资者提问：问公司吕董，二级市场上动不动出观数十万股的抛单，是否是大股东所为？京新药业回复：您好！公司大股东暂未有减持计划。谢谢！以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042100029469.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"gpt_icon":0},{"id":"2529809853","title":"京新药业：公司对于股份回购的操作会严格按照回购相关规则实施回购操作","url":"https://stock-news.laohu8.com/highlight/detail?id=2529809853","media":"证券之星","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529809853?lang=zh_cn&edition=full","pubTime":"2025-04-21 20:51","pubTimestamp":1745239879,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)04月21日在投资者关系平台上答复投资者关心的问题。投资者提问：问公司吕董，公司拿全体股东的钱7亿用于回购，而公司二级市场价格却如此表现，问对得起全体股东吗？另外公司找的操盘手是否合格？京新药业回复：您好!公司对于股份回购的操作，会严格按照回购相关规则实施回购操作。谢谢！以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042100029468.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"gpt_icon":0},{"id":"2518746268","title":"京新药业：目前的回购不会影响公司的正常经营，也不会影响正常的研发支出","url":"https://stock-news.laohu8.com/highlight/detail?id=2518746268","media":"证券之星","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518746268?lang=zh_cn&edition=full","pubTime":"2025-03-11 20:52","pubTimestamp":1741697547,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)03月10日在投资者关系平台上答复投资者关心的问题。投资者提问：公司提高回购总额上限，需要大量现金，公告说是自有资金，请问短期大量支出现金会影响正常经营活动吗？对这两年的研发支出和股东分红有影响吗？京新药业回复：您好！目前的回购不会影响公司的正常经营，也不会影响正常的研发支出。公司一向重视回报股东，会坚持分红回报股东。谢谢！以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025031100039520.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"gpt_icon":0},{"id":"2518462057","title":"京新药业：公司一向重视对股东的回报，最近几年也一直坚持高比例现金分红","url":"https://stock-news.laohu8.com/highlight/detail?id=2518462057","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518462057?lang=zh_cn&edition=full","pubTime":"2025-03-11 20:52","pubTimestamp":1741697536,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)03月10日在投资者关系平台上答复投资者关心的问题。投资者提问：问公司吕董，公司利用全体股东的真金白银4亿回购公司二级市场股票，请问耗费巨资为广大中小股东带来什么利益京新药业回复：您好！公司一向重视对股东的回报，最近几年也一直坚持高比例现金分红。关于回购的主要目的是股权激励或员工持股计划。公司考虑这些事项的核心，是充分围绕为股东创造价值和回报进行的。谢谢！以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025031100039514.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"gpt_icon":0},{"id":"2518219879","title":"京新药业：公司管线里的大品种基本都参与了集采，一些品种也经过了几轮续约","url":"https://stock-news.laohu8.com/highlight/detail?id=2518219879","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518219879?lang=zh_cn&edition=full","pubTime":"2025-03-10 16:57","pubTimestamp":1741597040,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)03月10日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘，请问公司有没有那款进医保的药参与了集采？或者说集采对于公司的利润有没有影响？京新药业回复：您好！公司管线里的大品种基本都参与了集采，一些品种也经过了几轮续约。公司会积极利用集采带来的准入机会，带动销售放量，努力实现公司利润的增长。谢谢！以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025031000022189.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"gpt_icon":0},{"id":"2518828218","title":"京新药业收盘上涨5.23%，滚动市盈率16.57倍，总市值119.51亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518828218","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518828218?lang=zh_cn&edition=full","pubTime":"2025-03-10 16:26","pubTimestamp":1741595160,"startTime":"0","endTime":"0","summary":"3月10日，京新药业今日收盘13.88元，上涨5.23%，滚动市盈率PE达到16.57倍，创307天以来新低，总市值119.51亿元。从行业市盈率排名来看，公司所处的化学制药行业市盈率平均46.69倍，行业中值26.68倍，京新药业排名第53位。股东方面，截至2024年9月30日，京新药业股东户数28693户，较上次减少1253户，户均持股市值35.28万元，户均持股数量2.76万股。最新一期业绩显示，2024年三季报，公司实现营业收入32.09亿元，同比9.68%；净利润5.75亿元，同比21.66%，销售毛利率51.11%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/10162648625651.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0239","002020"],"gpt_icon":0},{"id":"2517545480","title":"京新药业：公司目前AI在研发的应用还处在持续摸索阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2517545480","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517545480?lang=zh_cn&edition=full","pubTime":"2025-03-07 20:53","pubTimestamp":1741352017,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)03月07日在投资者关系平台上答复投资者关心的问题。投资者提问：公司有没有利用ai制成新药京新药业回复：您好！公司目前AI在研发的应用，还处在持续摸索阶段。谢谢！以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025030700042468.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"gpt_icon":0},{"id":"2517101464","title":"京新药业最新公告：调整回购资金上限至7亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517101464","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517101464?lang=zh_cn&edition=full","pubTime":"2025-03-07 17:40","pubTimestamp":1741340453,"startTime":"0","endTime":"0","summary":"京新药业(002020.SZ)公告称，公司将回购资金总额由“不低于人民币20,000万元(含)，不超过人民币40,000万元（含）”调整至“不低于人民币35,000万元(含)，不超过人民币70,000万元（含）”。除回购资金总额调整外，回购股份方案的其他内容未发生变化。本次调整属于董事会审批权限范围，无需提交股东大会审议。以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025030700030499.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"gpt_icon":0},{"id":"2517013911","title":"京新药业：调整回购资金上限至7亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517013911","media":"美港电讯","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517013911?lang=zh_cn&edition=full","pubTime":"2025-03-07 17:37","pubTimestamp":1741340248,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0239","002020"],"gpt_icon":0},{"id":"2517154385","title":"京新药业：目前控股股东尚无相关增持计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2517154385","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517154385?lang=zh_cn&edition=full","pubTime":"2025-03-06 20:51","pubTimestamp":1741265501,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)03月05日在投资者关系平台上答复投资者关心的问题。投资者提问：问公司吕董，既然公司都回购近4%的股份，那做为控股股东吕董你为什么不增持公司股份呢？京新药业回复：您好！目前控股股东尚无相关增持计划。若后续有相关事项推进，公司将严格按照相关要求及时履行信息披露义务，请关注公司信息披露公告。谢谢！以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025030600038097.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"gpt_icon":0},{"id":"2516351800","title":"京新药业(002020.SZ)累计回购3.01%股份 耗资3.2亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516351800","media":"智通财经网","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516351800?lang=zh_cn&edition=full","pubTime":"2025-03-02 16:14","pubTimestamp":1740903240,"startTime":"0","endTime":"0","summary":"京新药业(002020.SZ)发布公告，截至2025年2月28日，公司通过股份回购专用证券账户以集中竞价方式回购公司股份2593.6483万股，占公司目前总股本的3.01%，购买股份最高成交价为12.98元/股，购买股份最低成交价为11.86元/股，成交总金额为3.2亿元(不含交易费用)。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-03-02/doc-inenhafk7723768.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","002020"],"gpt_icon":0},{"id":"2516590908","title":"京新药业(002020.SZ)：累计回购3.01%公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2516590908","media":"格隆汇","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516590908?lang=zh_cn&edition=full","pubTime":"2025-03-02 15:49","pubTimestamp":1740901794,"startTime":"0","endTime":"0","summary":"格隆汇3月2日丨京新药业(002020.SZ)公布，截至2025年2月28日，公司通过股份回购专用证券账户以集中竞价方式回购公司股份2593.6483万股，占公司目前总股本的3.01%，购买股份最高成交价为12.98元/股，购买股份最低成交价为11.86元/股，成交总金额为31974.63万元（不含交易费用）。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/02154948475215.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0239","002020"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1746095579897,"stockEarnings":[{"period":"1week","weight":-0.0326},{"period":"1month","weight":-0.0401},{"period":"3month","weight":0.1152},{"period":"6month","weight":0.1026},{"period":"1year","weight":0.1818},{"period":"ytd","weight":0.0664}],"compareEarnings":[{"period":"1week","weight":-0.0053},{"period":"1month","weight":-0.017},{"period":"3month","weight":0.0087},{"period":"6month","weight":0.0021},{"period":"1year","weight":0.0561},{"period":"ytd","weight":-0.0217}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江京新药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"25705人(较上一季度减少85.40%)","perCapita":"0股","listingDate":"2004-07-15","address":"浙江省绍兴市新昌县羽林街道新昌大道东路800号","registeredCapital":"86102万元","survey":"　　浙江京新药业股份有限公司的主营业务是化学制剂、传统中药、生物制剂、化学原料药、医疗器械的研发、生产及销售。公司的主要产品是化学制剂、传统中药、生物制剂、化学原料药、医疗器械。公司是第一批“中国医药企业制剂国际化先导企业”，连续多年荣登“中国化学制药行业制剂出口型优秀企业品牌”、“中国医药工业百强”和“中国化学制药企业百强榜”。","listedPrice":10.05},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"京新药业(002020)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供京新药业(002020)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"京新药业,002020,京新药业股票,京新药业股票老虎,京新药业股票老虎国际,京新药业行情,京新药业股票行情,京新药业股价,京新药业股市,京新药业股票价格,京新药业股票交易,京新药业股票购买,京新药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"京新药业(002020)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供京新药业(002020)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}